[HTML][HTML] Amyloid β-Protein Inhibits Ubiquitin-dependent Protein Degradation in Vitro (∗)

L Gregori, C Fuchs, ME Figueiredo-Pereira… - Journal of Biological …, 1995 - ASBMB
Intraneuronal accumulation of ubiquitin conjugates in inclusion bodies and neurofibrillary
tangles is a pathological feature of neurodegenerative disorders such as Alzheimer's disease …

US Food and Drug Administration approval: Panitumumab for epidermal growth factor receptor–expressing metastatic colorectal carcinoma with progression following …

RM Giusti, K Shastri, AM Pilaro, C Fuchs… - Clinical Cancer …, 2008 - AACR
Purpose: To describe the Food and Drug Administration review and marketing approval
considerations for panitumumab (Vectibix) for the third-line treatment of patients with epidermal …

Approval summary: cetuximab in combination with cisplatin or carboplatin and 5‐fluorouracil for the first‐line treatment of patients with recurrent locoregional or …

MH Cohen, H Chen, S Shord, C Fuchs, K He… - The …, 2013 - academic.oup.com
Learning Objectives Compare survival outcomes among patients with SCCHN treated with
a platinum/5 ‐FU regimen with and without cetuximab. Compare adverse event profiles …

Notch‐1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds

LL Shelly, C Fuchs, L Miele - Journal of cellular biochemistry, 1999 - Wiley Online Library
Strikingly increased expression of notch‐1 has been demonstrated in several human
malignancies and pre‐neoplastic lesions. However, the functional consequences of notch‐1 …

Development and regulation of monoclonal antibody products: challenges and opportunities

…, A Weir, M Hartsough, P Keegan, C Fuchs - Cancer and metastasis …, 2005 - Springer
An increasing number of monoclonal antibodies for cancer diagnosis and treatment are in
clinical use and in the development pipeline, with more expected as new molecular targets …

FDA's approval of the first biosimilar to bevacizumab

SJ Casak, SJ Lemery, J Chung, C Fuchs… - Clinical Cancer …, 2018 - AACR
Passage of the Biologics Price Competition and Innovation Act of 2009 created an
abbreviated licensure pathway for biosimilar products. The FDA approved ABP215 (MVASI, …

Molecular cloning of gefiltin (ON1): serial expression of two new neurofilament mRNAs during optic nerve regeneration.

E Glasgow, RK Druger, C Fuchs, WS Lane… - The EMBO …, 1994 - embopress.org
The goldfish visual pathway displays a remarkable capacity for continued development and
plasticity. The intermediate filament proteins of this pathway do not match the intermediate …

Plasticin, a novel type III neurofilament protein from goldfish retina: increased expression during optic nerve regeneration

E Glasgow, RK Druger, EM Levine, C Fuchs… - Neuron, 1992 - cell.com
The goldfish visual pathway displays a remarkable capacity for continued development and
plasticity. The intermediate filament proteins in this pathway are unexpected and atypical, …

Complex expression of keratins in goldfish optic nerve

RK Druger, E Glasgow, C Fuchs… - Journal of …, 1994 - Wiley Online Library
Keratins are the predominant intermediate filament proteins in the nonneuronal cells of the
goldfish optic nerve. At least three different keratin pairs are expressed in this tissue, …

Plasticin, a newly identified neurofilament protein, is preferentially expressed in young retinal ganglion cells of adult goldfish

C Fuchs, E Glasgow, PF Hitchcock… - Journal of …, 1994 - Wiley Online Library
The adult goldfish retina and optic nerve display continuous growth, plasticity, and the
capacity to regenerate throughout the animal's life. The intermediate filament proteins in this …